Scandinavian ChemoTech presents at Redeye Fight Cancer Day
On January 19, 2023, Scandinavian ChemoTech's CEO Mohan Frick will present the company and its Tumour Specific Electroporation™ (TSE) technology for the treatment of cancer in humans and animals at the Redeye Fight Cancer Day event.
The presentation is scheduled for 15:25 CET and can be followed digitally via a live stream on Redeye's event page at the link below. On the same page, questions can be asked before the presentation.
https://www.redeye.se/events/868559/redeye-theme-fight-cancer
The presentation will be available afterwards on Scandinavian ChemoTech's website and via the company's YouTube channel:
https://www.youtube.com/@scandinavianchemotechabpub4074
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
